Fanconi anemia pathway-the way of DNA interstrand cross-link repair

Pharmazie

Volumn 68, Issue 1, 2013, Pages 5-11

  Yao, C J ^a,b   Du, W ^a   Zhang, Q ^a   Zhang, F ^a   Zeng, F ^b   Chen, F P ^b  

^a THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CHLORMETHINE; CISPLATIN; CURCUMIN; FANCONI ANEMIA GROUP D2 PROTEIN; FANCONI ANEMIA PROTEIN; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; MELPHALAN; MITOMYCIN; TEMOZOLOMIDE; CROSS LINKING REAGENT; DNA; UBIQUINONE;

DNA CROSS LINKING; DNA REPAIR; DRUG MECHANISM; FANCONI ANEMIA; GENE CONTROL; GENE MUTATION; HUMAN; NONHUMAN; ONCOGENE; REVIEW; TREATMENT FAILURE; TUMOR SUPPRESSOR GENE; UBIQUITINATION; GENETICS; METABOLISM; NEOPLASM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

CROSS-LINKING REAGENTS; DNA; DNA REPAIR; FANCONI ANEMIA; FANCONI ANEMIA COMPLEMENTATION GROUP PROTEINS; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; UBIQUINONE;

MLCS; MLOWN;

EID: 84875801883     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2013.2674     Document Type: Review

References (65)

1. Ali-Osman F, Rairkar A, Young P (1995) Formation and repair of 1,3-bis- (2-chloroethyl)-1-nitrosourea and cisplatin induced total genomic DNA interstrand crosslinks in human glioma cells. Cancer Biochem Biophys 14: 231-241.
2. Blackford AN, Schwab RA, Nieminuszczy J, Deans AJ, West SC, NiedzwiedzW(2012) The DNA translocase activity of FANCM protects stalled replication forks. Hum Mol Genet 21: 2005-2016.
3. Bordeleau L, Panchal S, Goodwin P (2010) Prognosis of BRCA-associated breast cancer: a summary of evidence. Breast Cancer Res Treat 119: 13-24.
4. Boukovinas I, Papadaki C, Mendez P, Taron M, Mavroudis D,Koutsopoulos A, Sanchez-Ronco M, Sanchez JJ, Trypaki M, Staphopoulos E, Georgoulias V, Rosell R, Souglakos J (2008) Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. PLoS One 3: e3695.
5. Buisson R, Dion-Cote AM, Coulombe Y, Launay H, Cai H, Stasiak AZ, Stasiak A, Xia B, Masson JY (2010) Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination. Nat Struct Mol Biol 17: 1247-1254.
6. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY (2003) Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97: 2187-2195.
7. Chappuis PO, Goffin J, Wong N, Perret C, Ghadirian P, Tonin PN, Foulkes WD (2002) A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet 39: 608-610.
8. Chen CC, Taniguchi T, D'Andrea A (2007) The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents. J Mol Med 85: 497-509.
9. Chen J, Dexheimer TS, Ai Y, Liang Q, Villamil MA, Inglese J, Maloney DJ, Jadhav A, Simeonov A, Zhuang Z (2011) Selective and cell-active inhibitors of the USP1/UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cells. Chem Biol 18: 1390-1400.
10. Chen Q, Van der Sluis PC, Boulware D, Hazlehurst LA, Dalton WS (2005) The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood 106: 698-705.
11. Cohn MA, Kee Y, Haas W, Gygi SP, D'Andrea AD (2009) UAF1 is a subunit of multiple deubiquitinating enzyme complexes. J Biol Chem 284: 5343-5351.
12. Collins NB, Wilson JB, Bush T, Thomashevski A, Roberts KJ, Jones NJ, KupferGM(2009)ATR-dependent phosphorylation of FANCAon serine 1449 afterDNAdamage is important for FApathway function. Blood 113: 2181-2190.
13. de Winter JP, van der Weel L, de Groot J, Stone S, Waisfisz Q, Arwert F, Scheper RJ, Kruyt FA, Hoatlin ME, Joenje H (2000) The Fanconi anemia protein FANCF forms a nuclear complex with FANCA, FANCC and FANCG. Hum Mol Genet 9: 2665-2674.
14. de Winter JP, Joenje H (2009) The genetic and molecular basis of Fanconi anemia. Mutat Res 668: 11-19.
15. Gari K, Decaillet C, DelannoyM,Wu L, ConstantinouA(2008) Remodeling of DNA replication structures by the branch point translocase FANCM. Proc Natl Acad Sci USA 105: 16107-16112.
16. Ho GP, Margossian S, Taniguchi T, D'Andrea AD (2006) Phosphorylation of FANCD2 on two novel sites is required for mitomycin C resistance. Mol Cell Biol 26: 7005-7015.
17. Huang M, Kim JM, Shiotani B, Yang K, Zou L, D'Andrea AD (2010) The FANCM/FAAP24 complex is required for the DNA interstrand crosslinkinduced checkpoint response. Mol Cell 39: 259-268.
18. Kim H, Yang K, Dejsuphong D, D'Andrea AD (2012) Regulation of Rev1 by the Fanconi anemia core complex. Nat Struct Mol Biol 19: 164-170.
19. Kim TM, Ko JH, Choi YJ, Hu L, Hasty P (2011) The phenotype of FancBmutant mouse embryonic stem cells. Mutat Res 712: 20-27.
20. Klein HL, Symington LS (2009) Breaking up just got easier to do. Cell 138: 20-22.
21. Leveille F, Blom E, Medhurst AL, Bier P, Laghmani EH, Johnson M, Rooimans MA, Sobeck A, Waisfisz Q, Arwert F, Patel KJ, Hoatlin ME, Joenje H, deWinter JP (2004) The Fanconi anemia gene product FANCF is a flexible adaptor protein. J Biol Chem 279: 39421-39430.
22. Leveille F, Ferrer M, Medhurst AL, Laghmani EH, Rooimans MA, Bier P, Steltenpool J, Titus TA, Postlethwait JH, and Hoatlin ME, Joenje H, de Winter JP (2006) The nuclear accumulation of the Fanconi anemia protein FANCE depends on FANCC. DNA Repair 5: 556-565.
23. Ling C, Ishiai M, Ali AM, Medhurst AL, Neveling K, Kalb R, Yan Z, Xue Y, Oostra AB, Auerbach AD, Hoatlin ME, Schindler D, Joenje H, de Winter JP, Takata M, Meetei AR, Wang W (2007) FAAP100 is essential for activation of the Fanconi anemia-associated DNA damage response pathway. Embo J 26: 2104-2114.
24. Ma J, Cai H, Wu T, Sobhian B, Huo Y, Alcivar A, Mehta M, Cheung KL, Ganesan S, Kong AN, Zhang DD, Xia B (2012) PALB2 Interacts with KEAP1 To Promote NRF2 Nuclear Accumulation and Function. Mol Cell Biol 32: 1506-1517.
25. Machida YJ, Machida Y, Chen Y, Gurtan AM, Kupfer GM, D'Andrea AD, Dutta A (2006) UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation. Mol Cell 23: 589-596.
26. Mazoyer S (2005) Genomic rearrangements in the BRCA1 and BRCA2 genes. Hum Mutat 25: 415-422.
27. McCauley J, Masand N, McGowan R, Rajagopalan S, Hunter A, Michaud JL, Gibson K, Robertson J, Vaz F, Abbs S, Holden ST (2011) X-linked VACTERL with hydrocephalus syndrome: further delineation of the phenotype caused by FANCB mutations. Am J Med Genet A 155A: 2370-2380.
28. Meetei AR, Levitus M, Xue Y, Medhurst AL, Zwaan M, Ling C, Rooimans MA, Bier P, Hoatlin M, Pals G, de Winter JP, Wang W, Joenje H (2004) X-linked inheritance of Fanconi anemia complementation group B. Nat Genet 36: 1219-1224.
29. Mimitou EP, Symington LS (2009) DNA end resection: many nucleases make light work. DNA Repair 8: 983-995.
30. Mitra A, Fisher C, Foster CS, Jameson C, Barbachanno Y, Bartlett J, Bancroft E, Doherty R, Kote-Jarai Z, Peock S, Easton D; IMPACT and EMBRACE Collaborators, Eeles R (2008) Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br J Cancer 98: 502-507.
31. Moldovan GL, D'Andrea AD (2009) How the fanconi anemia pathway guards the genome. Annu Rev Genet 43: 223-249.
32. Murai J, Yang K, Dejsuphong D, Hirota K, Takeda S, D'Andrea AD (2011) The USP1/UAF1 complex promotes double-strand break repair through homologous recombination. Mol Cell Biol 31: 2462-2469.
33. Nijman SM, Huang TT, Dirac AM, Brummelkamp TR, Kerkhoven RM, D'Andrea AD, Bernards R (2005) The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol Cell 17: 331-339.
34. Ochiai K, Yoshikawa Y, Oonuma T, Tomioka Y, Hashizume K, Morimatsu M(2011) Interactions between canine RAD51 and full length or truncated BRCA2 BRC repeats. Vet J 190: 293-295.
35. Park SJ, Beck BD, SaadatzadehMR,Haneline LS, ClappDW, LeeSH(2011) Fanconi anemia D2 protein is an apoptotic target mediated by caspases. J Cell Biochem 112: 2383-2391.
36. Pelttari LM, Heikkinen T, Thompson D, Kallioniemi A, Schleutker J, Holli K, Blomqvist C, Aittomaki K, Butzow R, Nevanlinna H (2011) RAD51C is a susceptibility gene for ovarian cancer. Hum Mol Genet 20: 3278-3288.
37. Poklar N, Pilch DS, Lippard SJ, Redding EA, Dunham SU, Breslauer KJ (1996) Influence of cisplatin intrastrand crosslinking on the conformation, thermal stability, and energetics of a 20-mer DNA duplex. Proc Natl Acad Sci USA 93: 7606-7611.
38. Qiao F, Mi J, Wilson JB, Zhi G, Bucheimer NR, Jones NJ, Kupfer GM (2004). Phosphorylation of fanconi anemia (FA) complementation group Gprotein, FANCG, at serine 7 is important for function of the FApathway. J Biol Chem 279: 46035-46045.
39. Quinn JE, James CR, Stewart GE, Mulligan JM, White P, Chang GK, Mullan PB, Johnston PG, Wilson RH, Harkin DP (2007) BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 13: 7413-7420.
40. Rego MA, Harney JA, Mauro M, Shen M, Howlett NG (2012) Regulation of the activation of the Fanconi anemia pathway by the p21 cyclin-dependent kinase inhibitor. Oncogene 31: 366-375.
41. Saberwal G, Horvath E, Hu L, Zhu C, Hjort E, Eklund EA (2009) The interferon consensus sequence binding protein (ICSBP/IRF8) activates transcription of the FANCF gene during myeloid differentiation. J Biol Chem 284: 33242-33254.
42. Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Farrugia DJ, Couch FJ, Urban N, Taniguchi T (2008) Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451: 1116-1120.
43. Sarkies P, Murat P, Phillips LG, Patel KJ, Balasubramanian S, Sale JE (2012) FANCJ coordinates two pathways that maintain epigenetic stability at G-quadruplex DNA. Nucleic Acids Res 40: 1485-1498.
44. Sato K, Toda K, Ishiai M, Takata M, Kurumizaka H (2012) DNA robustly stimulates FANCD2 monoubiquitylation in the complex with FANCI. Nucleic Acids Res 40: 4553-4561.
45. Smogorzewska A, Desetty R, Saito TT, Schlabach M, Lach FP, Sowa ME, Clark AB, Kunkel TA, Harper JW, Colaiacovo MP Elledge SJ (2010) A genetic screen identifies FAN1, a Fanconi anemia-associated nuclease necessary for DNA interstrand crosslink repair. Mol Cell 39: 36-47.
46. Smogorzewska A, Matsuoka S, Vinciguerra P, McDonald ER, Hurov KE, Luo J, Ballif BA, Gygi SP, Hofmann K, D'Andrea AD, Elledge SJ (2007) Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell 129: 289-301.
47. Solyom S, Winqvist R, Nikkila J, Rapakko K, Hirvikoski P, Kokkonen H, Pylkas K (2011) Screening for large genomic rearrangements in the FANCA gene reveals extensive deletion in a Finnish breast cancer family. Cancer Lett 302: 113-118.
48. Somyajit K, Subramanya S, Nagaraju G (2010) RAD51C: a novel cancer susceptibility gene is linked to Fanconi anemia and breast cancer. Carcinogenesis 31: 2031-2038.
49. Somyajit K, Subramanya S, Nagaraju G (2012) Distinct roles of FANCO/RAD51C protein in DNA damage signaling and repair: implications for Fanconi anemia and breast cancer susceptibility. J Biol Chem 287: 3366-3380.
50. Stecklein SR, Jensen RA, Pal A (2012) Genetic and epigenetic signatures of breast cancer subtypes. Front Biosci (Elite Ed) 4: 934-949.
51. Strathdee CA, Gavish H, Shannon WR, Buchwald M (1992) Cloning of cDNAs for Fanconi's anaemia by functional complementation. Nature 356: 763-767.
52. Suhasini AN, Brosh RJ (2012) Fanconi anemia and Bloom's syndrome crosstalk through FANCJ-BLM helicase interaction. Trends Genet 28: 7-13.
53. Svendsen JM, Smogorzewska A, Sowa ME, O'Connell BC, Gygi SP, Elledge SJ, Harper JW (2009) Mammalian BTBD12/SLX4 assembles a Holliday junction resolvase and is required for DNA repair. Cell 138: 63-77.
54. Tao Y, Jin C, Li X, Qi S, Chu L, Niu L, Yao X, TengM(2012) The structure of the FANCM-MHF complex reveals physical features for functional assembly. Nat Commun 3: 782.
55. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT (1995) Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 9: 444-450.
56. Tumini E, Plevani P, Muzi-Falconi M, Marini F (2011) Physical and functional crosstalk between Fanconi anemia core components and the GINS replication complex. DNA Repair 10: 149-158.
57. van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, Hoogerbrugge N, Verhoef S, Vasen HF, Ausems MG, Menko FH, Gomez GE, Klijn JG, Hogervorst FB, van Houwelingen JC, van't Veer LJ, Rookus MA, van Leeuwen FE (2005) Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 42: 711-719.
58. Wang W (2008). A major switch for the Fanconi anemia DNA damageresponse pathway. Nat Struct Mol Biol 15: 1128-1130.
59. Wang X, Kennedy RD, Ray K, Stuckert P, Ellenberger T, D'Andrea AD (2007) Chk1-mediated phosphorylation of FANCE is required for the Fanconi anemia/BRCA pathway. Mol Cell Biol 27: 3098-3108.
60. Wang Y,Wiltshire T, Senft J,Wenger SL, Reed E,WangW(2006) Fanconi anemia D2 protein confers chemoresistance in response to the anticancer agent, irofulven. Mol Cancer Ther 5: 3153-3161.
61. Wu Q, Christensen LA, Legerski RJ, Vasquez KM (2005) Mismatch repair participates in error-free processing of DNA interstrand crosslinks in human cells. Embo Rep 6: 551-557.
62. Xiao H, Xiao Q, Zhang K, Zuo X, ShresthaUK(2010) Reversal of multidrug resistance by curcumin through FA/BRCA pathway in multiple myeloma cell line MOLP-2/R. Ann Hematol 89: 399-404.
63. Yamamoto KN, Kobayashi S, Tsuda M, Kurumizaka H, Takata M, Kono K, Jiricny J, Takeda S, Hirota K (2011) Involvement of SLX4 in interstrand cross-link repair is regulated by the Fanconi anemia pathway. Proc Natl Acad Sci USA 108: 6492-6496.
64. Zhang J, Zhao D, Wang H, Lin CJ, Fei P (2008) FANCD2 monoubiquitination provides a link between the HHR6 and FA-BRCA pathways. Cell Cycle 7: 407-413.
65. Zhang Y, Zhou X, Zhao L, Li C, Zhu H, Xu L, Shan L, Liao X, Guo Z, Huang P (2011) UBE2W interacts with FANCL and regulates the monoubiquitination of Fanconi anemia protein FANCD2. Mol Cells 31: 113-122.